Pepromene

PeproMene Bio, Inc. is a clinical-stage biotechnology company based in Irvine, California, committed to developing novel immune therapies to treat cancers and immune disorders. The company's lead program is its BAFF-R CAR-T therapy, based on a novel antibody targeting the B-cell Activating Factor Receptor (BAFF-R) discovered by Dr. Larry Kwak's team at MD Anderson Cancer Center and City of Hope National Medical Center. BAFF-R is an excellent target for B-cell cancers due to its specificity and expression levels in lymphoproliferative and leukemia-proliferative disorders. PeproMene Bio's pipeline includes PMB-101 for relapsed/refractory B-cell acute lymphoblastic leukemia and PMB-102 for relapsed/refractory mantle cell lymphoma, with additional programs targeting B-cell malignancies and autoimmune disorders. The company's BAFFR-CAR T cell therapy has demonstrated polyfunctionality and durable responses in clinical settings, including efficacy after prior CD19 CAR-T cell failure, and received an oral presentation at EHA 2026.